LaKE Pharma Completes 24-Week LAE102 Study, Initiates High-Dose Cohort

According to LaKE Pharma's announcement, the company recently completed a 24-week monotherapy study of LAE102 in the low-dose cohort, with consistent results from prior single-ascending-dose (SAD) and multiple-ascending-dose (MAD) studies. The low-dose group showed encouraging weight loss effects with observed increases in muscle mass and decreases in fat mass, while demonstrating good tolerability with no serious adverse events reported, and no cases of diarrhea, muscle cramps, or acne.

The high-concentration formulation of LAE102 is now ready, and the company has completed patient enrollment for the high-dose cohort to further evaluate efficacy and safety over the 24-week treatment period.

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate US. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate US does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments involve high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.
Comment
0/400
No comments